Cardiff Oncology, Inc. (CRDF) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
050K100K150K200K250K300K350K400KQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Operating Expenses

Research And Development ExpensesSelling General And Administrative ExpensesOther Expenses
02M5M8M10M12M15M18M20MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025

EBITDA

EBITDA
-20M-17M-15M-12M-10M-7M-5M-2M1Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

EPS

Revenue Variation (%)

Revenue Variation
-40-32-25-18-10-251220Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Income Variation (%)

Gross Profit VariationOperating Income Variation
02581012151820Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Revenue YoY Variation (%)

Revenue YoY Variation
-60-52-45-37-30-22-14-71Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
03875112150188225262300Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Price-to-Earning Ratio

P/E Ratio
-8-7-6-5-4-2-1-01Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
0750K2M2M3M4M4M5M6MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
0255075100125150175200Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
08M15M22M30M38M45M52M60MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
08M15M22M30M38M45M52M60MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025
🏦 Balance Sheet
📈 Key Metrics